Lenalidomide Teva (Lenalidomide)

Lenalidomide is an immunomodulatory agent used in hematologic malignancies.

• Multiple Myeloma: improves progression‑free survival, overall response rates, and depth of response in patients with relapsed or refractory disease, often in combination with dexamethasone.
• Myelodysplastic Syndromes with del(5q): reduces red blood cell transfusion dependence, can induce cytogenetic remission, and prolongs survival in patients with this specific chromosomal deletion.
• Mantle Cell Lymphoma: provides disease control and extends progression‑free survival in patients who have received prior lines of therapy, including those refractory to conventional chemotherapy.

• Lenalidomide binds to the cereblon component of the CRL4^CRBN E3 ubiquitin ligase complex, altering substrate specificity. This leads to ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in anti‑angiogenic activity, modulation of cytokine production, enhanced immune‑mediated tumor cell killing, and direct antiproliferative effects on malignant plasma cells, and contributes to disruption of the tumor microenvironment.

Lenalidomide may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Fatigue: persistent tiredness that may affect daily activities.
• Diarrhea: loose stools occurring intermittently, sometimes with abdominal cramping.
• Nausea: sensation of sickness that can lead to occasional vomiting.
• Rash: skin redness or mild eruptions that may be itchy.
• Peripheral edema: swelling of hands, feet, or ankles without pain.

Serious or Rare Side Effects

• Thromboembolic events: deep vein thrombosis or pulmonary embolism, requiring immediate medical attention.
• Severe neutropenia: markedly low neutrophil count, increasing susceptibility to infections.
• Severe thrombocytopenia: low platelet count that can result in bruising or bleeding.
• Secondary primary malignancies: development of new, unrelated cancers during treatment.
• Hypersensitivity reactions: severe skin reactions such as Stevens‑Johnson syndrome or systemic anaphylaxis.

When prescribing Lenalidomide, several precautions and warnings should be observed to minimize risks.

• Pregnancy contraindication: drug is category X; avoid use in pregnant women and ensure effective contraception.
• Thromboembolic risk: assess patient history and consider prophylactic anticoagulation when risk factors are present.
• Hematologic monitoring: perform regular complete blood counts to detect neutropenia or thrombocytopenia early.
• Renal impairment: adjust therapy and monitor kidney function in patients with reduced clearance.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Lenalidomide has known drug interactions that may require dose adjustment or close monitoring.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower lenalidomide levels and reduce efficacy.
• Anticoagulants (warfarin, DOACs): increase bleeding risk; monitor coagulation parameters closely.

Moderate Interactions (Monitor Closely)

• Immunosuppressants (e.g., cyclosporine): can heighten hematologic toxicity, requiring frequent blood‑count monitoring.
• CYP3A4 inhibitors (e.g., ketoconazole): may modestly raise lenalidomide exposure, watch for side effects.
• Diuretics (e.g., furosemide): may affect renal clearance; assess hydration and kidney function.
• Live attenuated vaccines: immune response may be reduced; avoid vaccination during treatment.